Implementing outcomes based managed entry agreements for rare disease treatments: nusinersen and tisagenlecleucel

10 August 2021 - Enthusiasm for the use of outcomes based managed entry agreements to manage uncertainties apparent at the time ...

Read more →

Optimising managed access: lessons from the Cancer Drugs Fund

14 May 2021 - The desire, opportunity, and willingness to increase access to potentially life saving cancer treatments has mounted in ...

Read more →

Determinants of managed entry agreements in the context of health technology assessment: a comparative analysis of oncology therapies in four countries

29 January 2021 - Managed entry agreements are increasingly used to address uncertainties arising in the health technology assessment process due ...

Read more →

The impact of managed entry agreements on pharmaceutical prices

6 July 2020 - Managed entry agreements have been used for several years, with the aim of curbing the growth of ...

Read more →

Innovative pharmaceutical pricing agreements in five European markets: A survey of stakeholder attitudes and experience

31 May 2018 - Innovative pricing agreements for medicines have been used in European markets for more than 20 years, ...

Read more →

A managed access approach to appraising new cancer drugs in England

12 January 2018 - The changing regulatory landscape brings new challenges to health technology assessment. Marketing authorisations are being granted as ...

Read more →